COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A / S (OMX: BAVA) announced today that the company has recently been engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to provide its IMVANEX® smallpox vaccine in response to new cases of monkey pox in the UK. Two related cases have been confirmed and admitted to a Liverpool hospital. One of them was most likely infected in Africa, where the family arrived a few days before the onset of the disease, and a sibling case was most likely infected on British soil with the first case.
Monkey pox is a rare but serious disease endemic in Central and West Africa. The disease is quite similar to human smallpox, although it is less severe with an estimated death rate of 1-10%.
IMVANEX (MVA-BN) is approved by the European Commission for active immunization against smallpox, but has also received approval for monkey pox by the United States Food and Drug Administration (FDA) and Health Canada, as the only vaccine approved for this indication in these territories. Bavarian Nordic previously delivered IMVANEX to PHE as part of the first human cases of monkey pox in the UK in 2018 and later in 2019, when several unrelated human cases were imported from Nigeria with subsequent infection by a professional. of health in the United Kingdom.
Paul Chaplin, CEO of Bavarian Nordic, said: “We are delighted to assist Public Health England quickly in such an emergency. Vaccination is an essential measure to prevent and control the spread of disease around the world. Governments have a vital role in preparing for epidemics by stocking vaccines and treatments so that they are readily available during events like this. We have long worked with other governments to strengthen their national epidemic preparedness, and we urge more countries to actively examine and mitigate the risks of diseases like monkey pox, which is sadly on the rise in Africa and has shown in recent years to cross borders several times.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacture and marketing of life-saving vaccines. We are a world leader in smallpox vaccines and have been a long-term supplier to the US government of a non-replication smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio additionally contains the market leading vaccine Rabipur®/ RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unleashing the potency of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to developing a next-generation COVID-19 vaccine based on licensed capsid virus-like particle technology. The vaccine candidate, ABNCoV2, is currently undergoing clinical studies. For more information visit www.bavarian-nordic.com.
Europe: Rolf Sass Sørensen, Vice-President Investor Relations, Tel. : +45 61 77 47 43
United States: Graham Morrell, Paddock Circle Advisors, [email protected], Tel: +1 781 686 9600